3β-HSD
3β-HSD
3β-HSD (3β-Hydroxysteroid Dehydrogenase) is a key enzyme in the steroid hormone biosynthesis pathway, catalyzing the conversion of precursors such as pregnenolone and dehydroepiandrosterone (DHEA) into progesterone and androstenedione, which are further used to synthesize glucocorticoids, mineralocorticoids, androgens, and estrogens.
3β-HSD exists in multiple isoforms in both humans and mice. In humans, the main isoforms are HSD3B1 (placenta, skin, mammary gland) and HSD3B2 (adrenal glands, gonads), with HSD3B2 being essential for the biosynthesis of glucocorticoids, mineralocorticoids, and sex hormones. In mice, 3β-HSD I is predominantly expressed in the adrenal glands and gonads, playing a key role in steroidogenesis, whereas 3β-HSD VI is expressed in the decidua and trophoblast cells during early pregnancy, regulating progesterone synthesis and potentially supporting embryo survival through immune suppression.
3β-HSD plays a crucial role in steroid biosynthesis, placental function, sex hormone metabolism, and endocrine disorders. HSD3B2 mutations can cause congenital 3β-HSD deficiency, leading to adrenal insufficiency, abnormal sexual development, and electrolyte imbalance. Dysregulation of HSD3B1 and HSD3B2 activity can result in androgen excess, contributing to polycystic ovary syndrome (PCOS). Moreover, HSD3B1 dysfunction has been implicated in recurrent early pregnancy loss, while 3β-HSD V, primarily expressed in the male liver, may promote the progression of androgen-dependent prostate cancer when aberrantly expressed[1].
3β-HSD Isoform Specific Products
All Product Categories
-
3β-HSD Related Products (7)
Related Products (7)
-
3β-HSD Isoform Comparison
-
Trilostane
0 ImagesSynonyms: Win 24540
-
HEAL-116
0 ImagesHEAL-116 is a potent, specific and orally active 3β-hydroxysteroid dehydrogenase type 1 (3βHSD1) inhibitor with an IC50 of 1.18 μM and a KD of 1.32 μM. HEAL-116 inhibits DHEA (HY-14650) metabolism and DHEA-induced target gene expression and cell proliferation. HEAL-116 can be used for cancer research, such as prostate cancer.
-
Epostane
0 ImagesCat. No.: HY-105128CAS No.: 80471-63-2Synonyms: WIN 32729Epostane (WIN 32729) is an orally active inhibitor for 3β-hydroxysteroid dehydrogenase, with IC50 of 1.45 nM. Epostane blocks ovulation and pregnancy in rats.
-
2,2-Bis(p-hydroxyphenyl)-1,1,1-trichloroethane-d8
0 ImagesCat. No.: HY-141764SCAS No.: 1794780-53-22,2-Bis(p-hydroxyphenyl)-1,1,1-trichloroethane-d8 is the deuterated-labeled HPTE (HY-W490804). HPTE is the active in vivo metabolite of Methoxychlor (HY-B1873), and acts as an inhibitor of 3β‑HSD and 17β‑HSD3. HPTE binds to the substrate-binding pocket of 3β‑HSD in a non-competitive manner, but competitively occupies the coenzyme NAD+-binding site, thereby inhibiting the conversion of pregnenolone to progesterone. HPTE binds to the androstenedione-binding pocket (the substrate pocket) of 17β‑HSD3 in a non-competitive manner, and competitively occupies the coenzyme NADPH-binding site, thus blocking the conversion of androstenedione to testosterone. HPTE interferes with androgen biosynthesis in Leydig cells by inhibiting the activities of these two key steroidogenic enzymes. HPTE can be used in studies related to androgen biosynthesis.
-
Trilostane-15N,d3
0 ImagesCat. No.: HY-14281S1Synonyms: Win 24540-15N,d3Trilostane-15N,d3 (Win 24540-15N,d3) is the deuterium labeled Trilostane (HY-14281). Trilostane (Win 24540) is a competitive and orally active 3-β-hydroxysteroiddehydrogenase (3β-HSD) inhibitor. Trilostane is a synthetic nonhormonal steroid. Trilostane can be used for the research of breast cancer and prostate cancer.
-
3βHSD1-IN-1
0 ImagesCat. No.: HY-174244CAS No.: 3082852-63-63βHSD1-IN-1 (Compound 46) is a 3β-hydroxysteroid dehydrogenase 1 (3βHSD1) inhibitor with an IC50 of 55 nM. 3βHSD1-IN-1 can effectively inhibit androgen receptor activity. 3βHSD1-IN-1 can be used in the research of diseases such as prostate cancer.
-
HPTE
0 ImagesCat. No.: HY-W490804CAS No.: 2971-36-0HPTE is the active in vivo metabolite of Methoxychlor (HY-B1873), and acts as an inhibitor of 3β‑HSD and 17β‑HSD3. HPTE binds to the substrate-binding pocket of 3β‑HSD in a non-competitive manner, but competitively occupies the coenzyme NAD+-binding site, thereby inhibiting the conversion of pregnenolone to progesterone. HPTE binds to the androstenedione-binding pocket (the substrate pocket) of 17β‑HSD3 in a non-competitive manner, and competitively occupies the coenzyme NADPH-binding site, thus blocking the conversion of androstenedione to testosterone. HPTE interferes with androgen biosynthesis in Leydig cells by inhibiting the activities of these two key steroidogenic enzymes. HPTE can be used in studies related to androgen biosynthesis.
